EFFECT OF ESCITALOPRAM ALONE OR COMBINATION WITH SORAFENIB ON HEPG2 HEPATOCELLULAR CELL LINE PROLIFERATION
EFFECT OF ESCITALOPRAM ALONE OR COMBINATION WITH SORAFENIB ON HEPG2 HEPATOCELLULAR CELL LINE PROLIFERATION

Summary/Abstract: HEPATOCELLULAR CARCINOMA IS ONE OF THE MOST COMMON CANCERS. THE MAIN TREATMENT FOR HEPATOCELLULAR CANCERS IS SURGERY. DRUG TREATMENT CAN BE PERFORMED IN ADVANCED CASES AFTER SURGICAL TREATMENT OR RELAPSE THERAPY. SORAFENIB IS A DRUG THAT IS USED PRIMARILY IN THE TREATMENT OF HEPATOCELLULAR CANCER. ESCITALOPRAM IS A DRUG IN THE SEROTONIN REUPTAKE INHIBITOR GROUP USED TO TREAT DEPRESSION. THERE ARE STUDIES SHOWING THE EFFECT OF ESCITALOPRAM ON PROLIFERATION. THE PURPOSE OF THIS STUDY IS TO EVALUATE THE USE OF ESCITALOPRAM ALONE AND IN COMBINATION WITH SORAFENIB IN LIVER CANCER. THE EFFECT OF ESCITALOPRAM AND IN COMBINATION ON PROLIFERATION OF HEPATOCELLULAR CELL LINES WAS ASSESSED BY XTT PROLIFERATION ASSAY. THE HALF INHIBITING CONCENTRATİON (IC 50) WAS CALCULATED BY REGRESSION ANALYSIS, PHOTOGRAPHED UNDER AN İNVERTED MİCROSCOPE. THE SYNERGISTIC EFFECT HAS BEEN EVALUATED. THE EFFECT ON MORPHOLOGİCAL CHANGES WAS VISUALIZED UNDER THE INVERTED MICROSCOPE. THE RESULTS OF OUR STUDY CONFIRM THE SYNERGISTIC EFFECT OF USE OF ESCITALOPRAM IN COMBINATION WITH SORAFENIB IN LIVER CANCER. PROSPECTIVE RANDOMIZED TRIALS ARE NEEDED TO EVALUATE ITS CLINICAL USE.

• Details
• Contents